ICRA An Affiliate of Moody's

About Us
About Us

ICRA Limited is an Independent and professional investment information & Credit Rating Agency.
Know more
Profile

ICRA Limited

Vision & Values

To be the preferred partner in providing best in class ...

Leadership

ICRA Limited

The ICRA Group

ICRA Limited

CSR & Sustainability

ICRA envisions to make stronger communities ...

Life At ICRA

Life at ICRA inspires you to give your best and make most ...

Moody's.com

ICRA Limited

Company Announcements

Keep stakeholders informed about important updates
Ratings
Ratings

As an early entrant in the Credit Rating business, ICRA Limited (ICRA) is one of the most experienced Credit Rating
Know more
Ratings Coverage

Corporate Debt Ratings

Financial Sector Ratings

Structured Finance Ratings

Infrastructure Sector Ratings

Other Ratings
Approach & Methodologies

Rating Methodologies

Rating Scale

Guide to Credit Ratings

Ratings Performance

FAQ
Rating Rationales

Allchem Lifescience Limited: Ratings reaffirmed; outlook revised to stable from positive; rated amount enhanced 10 Jun 2026

DLF Info Park Developers (Chennai) Limited: Rating Assigned 10 Jun 2026

DLF Cyber City Developers Limited: Ratings reaffirmed 10 Jun 2026
Research
ICRA Research

ICRA industry research provides unique research offering for 60+ sectors in India wherein 250+ Ratings analysts
Know more
Research Offerings

Banking & Financial Services

Economy

Outlook

Corporate

Climate Series

Cross-sectoral trends & outlook

Structured Finance
Special Comments

Fuel price increase to compress industry margins; organised players better positioned with fuel pass-through clauses and operational efficiencies 10 Jun 2026

India’s current account saw surplus of $7.1 billion in Q4, amid surge in remittances; CAD may widen to ~1.7% of GDP in FY2027, with upside risks 08 Jun 2026

Monthly Research Compendium 05 Jun 2026
Most Trending Reports

Electricity demand growth to rebound in FY2027; tariff hikes remain nil 29 May 2026

Volumes increased by 16.5% YoY in April 2026, driving a strong start to FY2027 29 May 2026

Demand remains resilient, though margins can face pressure from elevated raw material costs in FY2027 29 May 2026
Credit Perspective
About Credit Perspective Reports

ICRA industry research provides unique research offering for 60+ sectors in India wherein 250+ Ratings analysts
Know more
Special Comments

Fuel price increase to compress industry margins; organised players better positioned with fuel pass-through clauses and operational efficiencies 10 Jun 2026

India’s current account saw surplus of $7.1 billion in Q4, amid surge in remittances; CAD may widen to ~1.7% of GDP in FY2027, with upside risks 08 Jun 2026

Monthly Research Compendium 05 Jun 2026
Most Trending Research

Electricity demand growth to rebound in FY2027; tariff hikes remain nil 29 May 2026

Volumes increased by 16.5% YoY in April 2026, driving a strong start to FY2027 29 May 2026

Demand remains resilient, though margins can face pressure from elevated raw material costs in FY2027 29 May 2026
Explore Latest Reports
Find now
Media
Media & Events

Insights, Events & News Coverage

Newsletter

Webinars

TV Coverage

Events

Podcast

Photo Gallery

Know more
Upcoming Webinars

No data available
What's in the news?

Fuelling the new normal - Business Standard 03 June 2026

Oman Goes Past Qatar to become India’s Top LNG Supplier in March - Economic Times 03 June 2026

Centre Meets FY26 Fiscal Deficit Target - Economic Times 02 June 2026
Contact Us

Login

Mankind Pharma Limited

Sector : Pharmaceuticals & Biotechnology Sub Sectors : Pharmaceuticals

10 Jun 2026 Mankind Pharma Limited: CPR-Mankind_Pharma_Limited

Home Credit Perspective Reports Mankind Pharma Limited

bg-rating-rationales

Entity-Specific Rating Rationales

12 May 2026

Mankind Pharma Limited: Ratings reaffirmed for existing instruments and assigned for commercial paper programme

Mankind Pharma Limited: Ratings reaffirmed for existing instruments and assigned for commercial paper programme

24 Feb 2026

Mankind Pharma Limited: Ratings reaffirmed

Mankind Pharma Limited: Ratings reaffirmed

16 Jan 2026

Mankind Pharma Limited: Rating withdrawn for Rs. 1,500 crore commercial paper programme; ratings outstanding for bank loan facilities and non-convertible debenture programme

Mankind Pharma Limited: Rating withdrawn for Rs. 1,500 crore commercial paper programme; ratings outstanding for bank loan facilities and non-convertible debenture programme

13 Nov 2025

Mankind Pharma Limited: Rating withdrawn for Rs. 3,500 crore commercial paper programme; ratings outstanding for bank loan facilities, non-convertible debenture programme and Rs. 1,500 crore commercial paper programme

Mankind Pharma Limited: Rating withdrawn for Rs. 3,500 crore commercial paper programme; ratings outstanding for bank loan facilities, non-convertible debenture programme and Rs. 1,500 crore commercial paper programme

25 Feb 2025

Mankind Pharma Limited: Long-term rating reaffirmed; short-term rating reaffirmed/ assigned

Mankind Pharma Limited: Long-term rating reaffirmed; short-term rating reaffirmed/ assigned

30 Sep 2024

Mankind Pharma Limited: Ratings reaffirmed for existing non-convertible debentures; ratings assigned for bank loans, commercial papers and non-convertible debentures

Mankind Pharma Limited: Ratings reaffirmed for existing non-convertible debentures; ratings assigned for bank loans, commercial papers and non-convertible debentures

05 Aug 2024

Mankind Pharma Limited - Update on Material Event

Mankind Pharma Limited - Update on Material Event

09 Jul 2024

Mankind Pharma Limited: Rating assigned

Mankind Pharma Limited: Rating assigned

bg-rating-crediet-reports

Entity-Specific Credit Perspective Reports

10 Jun 2026

Mankind Pharma Limited

Mankind Pharma Limited (Non-SF)

25 Mar 2026

Mankind Pharma Limited

Mankind Pharma Limited (Non-SF)

26 Mar 2025

Mankind Pharma Limited

Mankind Pharma Limited (Non-SF)

29 Oct 2024

Mankind Pharma Limited

Mankind Pharma Limited (Non-SF)

02 Sep 2024

Mankind Pharma Limited

Mankind Pharma Limited (Non-SF)

Ratings

Description	Short Term	Medium Term	Long Term	Issuer
NCD	--	--	[ICRA]AA+(Stable)	--
Commercial Paper	[ICRA]A1+	--	--	--
Long-term/Short-term – Fund-based – Proposed limits	[ICRA]A1+	--	[ICRA]AA+(Stable)	--
Commercial Papers	Withdrawn	--	--	--

Our Analysts

Analyst 1

Gaurav Kushwaha

2261143465
gaurav.kushwaha@icraindia.com

Analyst 2

Deepak Jotwani

+91 124 4545870
deepak.jotwani@icraindia.com

Sector Head

Jitin Makkar

9873339826
jitinm@icraindia.com

bg-rating-research

Most Trending Research Reports

View More

bg-rating-rationales

Rating Rationales

View More

Webinars

View all

No Data Available

Beyond renewables - Investment outlook and emerging role of thermal power

Girishkumar Kadam,Ankit Jain,Asmita Pant

07 May 2026 04:00 PM

Want to Listen

PPT

West Asia Crisis-Impact and Outlook on Oil & Gas and downstream sectors

Girishkumar Kadam,Prashant Vasisht

29 Apr 2026 04:00 PM

Want to Listen

View all

Podcast

Cement Sector Outlook | West Asia conflict and Cost Pressures | ICRA Podcast by Maitri Vira

May 2026

Media Release

Ask Our Industry Analyst Get in touch with our Business Representative

Please enter your name

Please enter your mobile number

Please enter your email id

Please enter your company name

Name should not be greater than 50 characters

Please choose sector

Please enter your query

Query to have atleast ten characters

Query should not be greater than 1,000 characters

Please verify you are not a Robot.